A Multicenter, Prospective, Randomized Trial of Intracoronary Administration of Ad5FGF-4 in Patients With No Revascularization Options - AGENT-3

Description:

Trial investigators evaluated angiogenesis-induction by fibroblast growth factor (Ad5FGF-4) as an alternative therapy for treating ischemic heart disease in patients who are suboptimal candidates for revascularization.